Royalty Pharma (RPRX) Change in Acquisitions & Divestments (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Change in Acquisitions & Divestments data on file, last reported at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 65.68% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $13.0 million (down 58.1% YoY), and the FY2025 full-year result was $21.2 million, up 7.28% from the prior year.
• Change in Acquisitions & Divestments advanced to $4.3 million in Q1 2026, from $2.9 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $274.6 million in Q1 2022 to a low of -$24.4 million in Q3 2023.
• A 5-year average of $53.9 million and a median of $8.5 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments surged 1657.49% in 2022 and slumped 116.17% in 2023, its largest moves.
• Tracing RPRX's Change in Acquisitions & Divestments over 5 years: stood at $115.6 million in 2022, then sank by 78.91% to $24.4 million in 2023, then tumbled by 48.4% to $12.6 million in 2024, then plunged by 77.12% to $2.9 million in 2025, then jumped by 50.0% to $4.3 million in 2026.
• Business Quant data shows RPRX's Change in Acquisitions & Divestments at $4.3 million in Q1 2026, $2.9 million in Q4 2025, and $2.9 million in Q3 2025.